Ganciclovir Triphosphate |
Catalog No.GN20172
One-Click Copy Product Info
|
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ganciclovir is a synthetic acyclic-DNA guanine derivative, where the C2' carbon bond is absent. Ganciclovir Triphosphate (ganciclovir-TP, GCV-TP), the active metabolite of ganciclovir, is thought to disrupt viral DNA synthesis by competitive inhibition of viral DNA polymerases and by incorporation into viral DNA, to result in eventual termination of viral DNA elongation. Ganciclovir was first published as 2'-Nor-2'-deoxyguanosine (2'NDG), with noted effectiveness in treating acute herpes simplex infections in mice. Recently it has been studied as an Epstein-Barr Virus treatment, as well as a prostate cancer, human cytomegalovirus (HCMV) retinitis and CMV antigeemia preemptive treatment. The triphosphorylated form (GCV-TP) is an important control in this research.
| purity | >95.00% | Extinction Coefficient | 13,600 Lmol-1cm-1 at 252 nm |
| Formula | C9H16N5O13P3 (free acid) | M.Wt | 495.20 g/mole (free acid) |
| Salt Form | Li+ | Concentration | 100 mM |
| Buffer | H2O | Storage | -20°C or below |
| Synonyms | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine-5'-Triphosphate, GCV-TP | Backbone | 5'-Triphosphate |
| Base Analog | Guanosine | Sugar Type | RNA |
| Nucleotide Category | Non-nucleotide | ||
| Applications | Aptamers | ||
Average Rating: 5 (Based on Reviews and 12 reference(s) in Google Scholar.)